risotilide profile

Risotilide is a potent and selective inhibitor of the human ether-à-go-go-related gene (hERG) potassium channel. This channel plays a critical role in the repolarization of the heart, and its inhibition can lead to life-threatening cardiac arrhythmias. Risotilide was originally developed as an antiarrhythmic drug, but it was withdrawn from clinical trials due to its potential to prolong the QT interval and increase the risk of torsades de pointes. However, risotilide has been shown to exhibit anti-inflammatory, anti-proliferative, and neuroprotective effects in various in vitro and in vivo studies. For example, risotilide has been shown to reduce inflammation and oxidative stress in models of inflammatory bowel disease and to protect neurons from damage in models of stroke. These findings suggest that risotilide may have therapeutic potential in a variety of diseases, although further research is needed to evaluate its safety and efficacy in humans.'

risotilide: class III anti-arrhythmia agent [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	60667
CHEMBL ID	2110984
SCHEMBL ID	123045
MeSH ID	M0176419

Synonym
risotilide
4-(methanesulfonamido)-n-propan-2-yl-n-[2-(propan-2-ylamino)ethyl]benzenesulfonamide
unii-46z36vje7h
120688-08-6
risotilide [inn]
46z36vje7h ,
SCHEMBL123045
4'-(isopropyl(2-(isopropylamino)ethyl)sulfamoyl)methanesulfonanilide
CHEMBL2110984
DTXSID90152966
n-isopropyl-n-(2-(isopropylamino)ethyl)-4-(methylsulfonamido)benzenesulfonamide
Q27258971
AKOS040747396

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	5 (62.50)	18.2507
2000's	2 (25.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (12.50)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (12.50%)	5.53%
Reviews	1 (12.50%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	6 (75.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
bethanidine Bethanidine: A guanidinium antihypertensive agent that acts by blocking adrenergic transmission. The precise mode of action is not clear.	1.97	1	guanidines	adrenergic antagonist; antihypertensive agent
verapamil Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.	1.97	1	aromatic ether; nitrile; polyether; tertiary amino compound
clofilium clofilium: RN given refers to parent cpd; structure	1.99	1	benzenes; organic amino compound
e 4031 E 4031: class III anti-arrhythmia agent; structure given in UD	3.08	1	sulfonamide
procainamide Procainamide: A class Ia antiarrhythmic drug that is structurally-related to PROCAINE.. procainamide : A benzamide that is 4-aminobenzamide substituted on the amide N by a 2-(diethylamino)ethyl group. It is a pharmaceutical antiarrhythmic agent used for the medical treatment of cardiac arrhythmias.	1.97	1	benzamides	anti-arrhythmia drug; platelet aggregation inhibitor; sodium channel blocker
tedisamil tedisamil : A member of the class of diazabicyclononanes that is (1s,5s)-3,7-diazaspiro[bicyclo[3.3.1]nonane-9,1'-cyclopentane] in which the hydrogens at positions 3 and 7 are replaced by cyclopropylmethyl groups. It is a potassium channel blocker and an antiarrhythmic agent currently currently in development for the treatment of atrial fibrillation.	1.97	1
uk 68798 [no description available]	2.39	2	aromatic ether; sulfonamide; tertiary amino compound	anti-arrhythmia drug; potassium channel blocker
tetrodotoxin Tetrodotoxin: An aminoperhydroquinazoline poison found mainly in the liver and ovaries of fishes in the order TETRAODONTIFORMES, which are eaten. The toxin causes paresthesia and paralysis through interference with neuromuscular conduction.. tetrodotoxin : A quinazoline alkaloid that is a marine toxin isolated from fish such as puffer fish. It has been shown to exhibit potential neutotoxicity due to its ability to block voltage-gated sodium channels.	3.08	1	azatetracycloalkane; oxatetracycloalkane; quinazoline alkaloid	animal metabolite; bacterial metabolite; marine metabolite; neurotoxin; voltage-gated sodium channel blocker
piperidines Piperidines: A family of hexahydropyridines.	3.08	1

Condition	Relationship Strength	Studies	Trials
Pregnancy in Diabetes [description not available]	2.41	1	0
Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).	2.41	1	0
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	2.41	1	0
Bleeding [description not available]	3.43	1	1
Hemorrhage Bleeding or escape of blood from a vessel.	3.43	1	1
Coronary Restenosis Recurrent narrowing or constriction of a coronary artery following surgical procedures performed to alleviate a prior obstruction.	3.43	1	1
Acute Coronary Syndrome An episode of MYOCARDIAL ISCHEMIA that generally lasts longer than a transient anginal episode that ultimately may lead to MYOCARDIAL INFARCTION.	3.43	1	1
Chronic Hepatitis B [description not available]	2.03	1	0
Chronic Hepatitis C [description not available]	2.03	1	0
Hepatocellular Carcinoma [description not available]	2.03	1	0
Cirrhosis, Liver [description not available]	2.03	1	0
Cancer of Liver [description not available]	2.03	1	0
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	2.03	1	0
Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.	2.03	1	0
Liver Neoplasms Tumors or cancer of the LIVER.	2.03	1	0
Hepatitis B, Chronic INFLAMMATION of the LIVER in humans caused by HEPATITIS B VIRUS lasting six months or more. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.	2.03	1	0
Hepatitis C, Chronic INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS.	2.03	1	0
Cardiac Hypertrophy Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.	1.97	1	0
Tachyarrhythmia [description not available]	1.97	1	0
Cardiomegaly Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.	1.97	1	0
Tachycardia Abnormally rapid heartbeat, usually with a HEART RATE above 100 beats per minute for adults. Tachycardia accompanied by disturbance in the cardiac depolarization (cardiac arrhythmia) is called tachyarrhythmia.	1.97	1	0
Ventricular Fibrillation A potentially lethal cardiac arrhythmia that is characterized by uncoordinated extremely rapid firing of electrical impulses (400-600/min) in HEART VENTRICLES. Such asynchronous ventricular quivering or fibrillation prevents any effective cardiac output and results in unconsciousness (SYNCOPE). It is one of the major electrocardiographic patterns seen with CARDIAC ARREST.	2.38	2	0
Atrioventricular Nodal Reentrant Tachycardia [description not available]	1.97	1	0
Tachycardia, Supraventricular A generic expression for any tachycardia that originates above the BUNDLE OF HIS.	1.97	1	0

risotilide

Description

Cross-References

Synonyms (13)

Research

Studies (8)

Market Indicators

Research Demand Index: 11.93

Study Types